HBF

Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 10, 2022
Trial of the century, HBG2, Neoplasm, SCD, Ink, Genetics, Eye, Annual report, NCT, HBF, Stem cell, Sickle cell disease, HPFH, CRISPR/Cpf1, Selection, FDA, Fetal hemoglobin, USH2A, Bristol Myers Squibb, Gene editing, Cas9, Cell, Private Securities Litigation Reform Act, Company, Potency (pharmacology), Technology, CRISPR, IPSC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, TDT, Clinical trial, CD34, Safety, Efficiency, European Medicines Agency, EST, Patient, Cell proliferation, Regenerative medicine, Food, Research, Nasdaq, AAV, B cell, BMS, GLOBE, Retinal degeneration, Cancer, Conference, Adult, IND, Forward-looking statement, Retinitis pigmentosa, HBG1, U.S. Securities and Exchange Commission, Birth defect, NK, EMA, Pharmaceutical industry, Medical imaging, Vaccine, Editas Medicine

CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that James C. Mullen, Chairman, President, and Chief Executive Officer, will discuss the Company’s recent progress and outlook for its gene editing medicines and platform technology at the 40th Annual J.P. Morgan Healthcare Conference being held virtually on Wednesday, January 12 at 10:30 a.m. EST.

Key Points: 
  • Using a dual-vector approach with a AsCas12a nuclease, Editas Medicine has enhanced productive editing by approximately 350% compared to the initial construct.
  • Editas Medicine has announced the development candidate EDIT-202, a highly differentiated, iPSC-derived natural killer cell (iNK) investigational medicine with double knock-in and double knock-out edits.
  • Editas Medicine continues to evaluate the application of its iPSC platform to additional cell types beyond iNK and alpha-beta T cells.
  • Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases.

Fulcrum Therapeutics® Announces Upcoming Milestones to Support Its Mission of Treating the Root Cause of Rare Genetic Diseases

Retrieved on: 
Monday, January 10, 2022
Liver disease, Losmapimod, Pain, Investigational New Drug, Sickle cell disease, Growth, Muscular dystrophy, Facioscapulohumeral muscular dystrophy, Biology, Stroke, Life expectancy, Infection, Investor relations, MAPK, Security (finance), Mutation, FSHD, Leadership, Patient, HBG, Conference, EED, IND, Gene expression, Q&A, Third Rock Ventures, U.S. Securities and Exchange Commission, Face, HIV disease progression rates, Anemia, HBF, Initiate, Review, Food, HBB, Therapy, DUX4, Food and Drug Administration, Private Securities Litigation Reform Act, Nasdaq, Degenerative disease, Movement, FDA, Disability, GLOBE, Pulmonary hypertension, Hemoglobinopathy, Thalassemia, GSK, Population, Kidney failure, Fetal hemoglobin, Pharmaceutical industry, Management, Fine chemical, Vaccine, Fulcrum

CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today outlined its recent accomplishments and expected upcoming milestones. Fulcrum will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13 at 12:00 p.m. ET. A live webcast will be available on the Investor Relations section of Fulcrum’s website.

Key Points: 
  • Fulcrum will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13 at 12:00 p.m.
  • Fulcrum made substantial progress in 2021, positioning us for a transformative 2022, said Bryan Stuart, president and chief executive officer.
  • As we enter 2022, we are building on this progress, with multiple milestones expected across our clinical and discovery-stage pipeline, Mr. Stuart continued.
  • Dosed first sickle cell disease patient in the Phase 1b clinical trial of FTX-6058, an oral fetal hemoglobin (HbF) inducer.

RETRANSMISSION: HIVE Blockchain Presents December 2021 Production and Calendar Year 2021 Figures

Retrieved on: 
Monday, January 10, 2022
ESG, Acquisition, Growth, HBF, Calendar, HODL, Legislation, BTC, ETC, Goal, TSX Venture Exchange, BCSC, ETH, FSE, Company, COO, Mining, YouTube, Offering, News, Follow, COVID-19, Twitter, HIVE, Application-specific integrated circuit, Animal, Cryptocurrency, Beekeeping, Ethereum, Bitcoin

Vancouver, British Columbia--(Newsfile Corp. - January 10, 2022) - HIVE Blockchain Technologies Ltd. (TSXV: HIVE) (Nasdaq: HIVE) (FSE: HBF) (the "Company" or "HIVE") is pleased to announce the production figures from the Company's global Bitcoin and Ethereum mining operations for the month of December 2021, with a BTC HODL balance of 1,813 Bitcoin as of December 31, 2021.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - January 10, 2022) - HIVE Blockchain Technologies Ltd. (TSXV: HIVE) (Nasdaq: HIVE) (FSE: HBF) (the "Company" or "HIVE") is pleased to announce the production figures from the Company's global Bitcoin and Ethereum mining operations for the month of December 2021, with a BTC HODL balance of 1,813 Bitcoin as of December 31, 2021.
  • HIVE is pleased to announce its December 2021 production figures.
  • The Company's total Bitcoin equivalent production in December 2021 was:
    In summary Total Bitcoin Equivalent mined was 3,222 based on BTC/ETH/ETC.
  • In addition to the BTC production represented by the chart below, with the Company's ETH and ETC mining, HIVE mined 3,222 BTC equivalent in 2021.

HIVE Blockchain Presents December 2021 Production and Calendar Year 2021 Figures

Retrieved on: 
Monday, January 10, 2022
ESG, Acquisition, Growth, HBF, Calendar, HODL, Legislation, BTC, ETC, Goal, TSX Venture Exchange, BCSC, ETH, FSE, Company, COO, Mining, YouTube, Offering, News, Follow, COVID-19, Twitter, HIVE, Application-specific integrated circuit, Animal, Cryptocurrency, Beekeeping, Ethereum, Bitcoin

Vancouver, British Columbia--(Newsfile Corp. - January 10, 2022) - HIVE Blockchain Technologies Ltd. (TSXV: HIVE) (Nasdaq: HIVE) (FSE: HBF) (the "Company" or "HIVE") is pleased to announce the production figures from the Company's global Bitcoin and Ethereum mining operations for the month of December 2021, with a BTC HODL balance of 1,813 Bitcoin as of December 31, 2021.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - January 10, 2022) - HIVE Blockchain Technologies Ltd. (TSXV: HIVE) (Nasdaq: HIVE) (FSE: HBF) (the "Company" or "HIVE") is pleased to announce the production figures from the Company's global Bitcoin and Ethereum mining operations for the month of December 2021, with a BTC HODL balance of 1,813 Bitcoin as of December 31, 2021.
  • HIVE is pleased to announce its December 2021 production figures.
  • The Company's total Bitcoin equivalent production in December 2021 was:
    In summary Total Bitcoin Equivalent mined was 3,222 based on BTC/ETH/ETC.
  • In addition to the BTC production represented by the chart below, with the Company's ETH and ETC mining, HIVE mined 3,222 BTC equivalent in 2021.

HIVE Blockchain Announces Filing of Prospectus Supplement and Automatic Exercise of Special Warrants

Retrieved on: 
Friday, January 7, 2022
Ethereum, Bitcoin, HBF, COVID-19, ESG, FSE, HIVE, Offering, Company, BTC, PI, BCSC, Goal, Follow, HODL, Twitter, Prospectus, SEDAR, NASDAQ, ETH, Stifel, Compliance, Legislation, News, YouTube, BMO Capital Markets, Security (finance), Cryptocurrency, Beekeeping

This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated February 2, 2021 to its short form base shelf prospectus dated January 27, 2021.

Key Points: 
  • The Prospectus Supplement qualifies for distribution 19,170,500 units (the "Units") issuable upon the automatic exercise of the Special Warrants for no additional consideration.
  • Each Warrant is exercisable for one Share on or before May 30, 2024 at an exercise price of $6.00 per Share.
  • For further information on the Special Warrants, please see the Company's news release dated November 30, 2021, a copy of which is available on SEDAR ( www.sedar.com ).
  • A copy of the Prospectus Supplement, including the documents incorporated by reference therein, is available under the Company's SEDAR profile at www.sedar.com .

Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo

Retrieved on: 
Thursday, January 6, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, EMA, Clinical trial, Therapy, COVID-19, Safety, Sickle cell disease, Global Research, Development, Program, BCL11A, Gene editing, Investor, Research, Patient, VOC, Stem cell, HBF, U.S. Securities and Exchange Commission, Company, ASH, Annual report, Week, CEO, SCD, FDA, Fast track (FDA), Collaboration, Technology, AES, Fetal hemoglobin, Nasdaq, Hemoglobinopathy, ESE, Anti-transglutaminase antibodies, Pharmaceutical industry, Vaccine, Sangamo Therapeutics, Sanofi, the PRECIZN-1 Study, Sangamo Therapeutics, THE PRECIZN-1 STUDY, SANGAMO THERAPEUTICS

The Companies are collaborating on an orderly transition, while Sangamo explores options to advance the program, including seeking a new collaboration partner.

Key Points: 
  • The Companies are collaborating on an orderly transition, while Sangamo explores options to advance the program, including seeking a new collaboration partner.
  • Sanofi has elected to transition the SCD program to Sangamo following a recent change in Sanofis cell therapy strategy.
  • Sangamo has been a good partner and this decision is not a reflection on the potential of the SAR445136 program.
  • We remain committed to progressing this program and believe SAR445136 has the potential to relieve people living with sickle cell disease of some of their most challenging symptoms.

HIVE Blockchain to Restate Previously Issued Annual Information Form

Retrieved on: 
Friday, December 31, 2021
Ethereum, Bitcoin, Twitter, Growth, BTC, COVID-19, Disclosure, AIF, Legislation, HIVE, Business operations, ETH, GLOBE, Company, ESG, News, British Columbia Securities Commission, FSE, HODL, Review, Nasdaq, Follow, HBF, Beekeeping, Animal, Cryptocurrency

VANCOUVER, British Columbia, Dec. 31, 2021 (GLOBE NEWSWIRE) -- HIVE Blockchain Technologies Ltd. (TSX.V:HIVE) (Nasdaq:HVBT) (FSE:HBF) (the “Company” or “HIVE”) announces that it has today filed a revised annual information form for the financial year ended March 31, 2021 (the “AIF”). The Company has made, among other changes, the following amendments to the AIF:  

Key Points: 
  • VANCOUVER, British Columbia, Dec. 31, 2021 (GLOBE NEWSWIRE) -- HIVE Blockchain Technologies Ltd. (TSX.V:HIVE) (Nasdaq:HVBT) (FSE:HBF) (the Company or HIVE) announces that it has today filed a revised annual information form for the financial year ended March 31, 2021 (the AIF).
  • About HIVE Blockchain Technologies Ltd.
    HIVE Blockchain Technologies Ltd. went public in 2017 as the first cryptocurrency mining company with a green energy and ESG strategy.
  • HIVE is a growth-oriented technology stock in the emergent blockchain industry.
  • The forward-looking information in this news release reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available to the Company.

HIVE Blockchain Provides Results from Shareholder Meeting, Review of 2021 Achievements and Corporate Update

Retrieved on: 
Wednesday, December 22, 2021
Bitcoin, Ethereum, ESG, FUD, ETH, Adoption, Nasdaq, Technology, Legislation, Fear, FSE, Ether, Mining, SEDAR, News, HIVE, Director, Twitter, Follow, NASDAQ, Investment, Growth, Acquisition, Proxy, Board of directors, New Year, Remuneration, COVID-19, YouTube, Board, BTC, Economics, The, GPU, TSX Venture Exchange, Company, HODL, Uncertainty, AGM, HBF, Calendar, Animal, Cryptocurrency, Beekeeping

This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated February 2, 2021 to its short form base shelf prospectus dated January 27, 2021.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - December 22, 2021) - HIVE Blockchain Technologies Ltd. (TSXV: HIVE) (NASDAQ: HIVE) (FSE: HBF) (the "Company" or "HIVE") is pleased to announce that all resolutions considered at its 2021 annual meeting of shareholders on December 21, 2021 were approved overwhelmingly by its shareholders.
  • The Company is also providing a corporate update for its fiscal third quarter ending December 31, 2021.
  • The Company has thus far in its fiscal third quarter, from October 1 to December 21, 2021, mined more than 6,280 Ether and 600 Bitcoin, based on the Company's preliminary unaudited results.
  • Since the beginning of 2021, HIVE has held in secure storage the majority of its ETH and BTC coin mining rewards.

HIVE Blockchain to Provide Corporate Update and Results from the 2021 Annual General Meeting

Retrieved on: 
Monday, December 20, 2021
Bitcoin, Ethereum, Twitter, Interim, News, COO, HBF, FSE, YouTube, NASDAQ, Webcast, Follow, TSX Venture Exchange, Hotel manager, HIVE, Beekeeping, Cryptocurrency

Vancouver, British Columbia--(Newsfile Corp. - December 20, 2021) - HIVE Blockchain Technologies Ltd. (TSXV: HIVE) (NASDAQ: HIVE) (FSE: HBF) (the "Company" or "HIVE") announces that management will host a webcast on Tuesday, December 21, 2021, at 4:00 p.m. Eastern Time to provide a corporate update and announce results from its 2021 Annual General Meeting of Shareholders.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - December 20, 2021) - HIVE Blockchain Technologies Ltd. (TSXV: HIVE) (NASDAQ: HIVE) (FSE: HBF) (the "Company" or "HIVE") announces that management will host a webcast on Tuesday, December 21, 2021, at 4:00 p.m. Eastern Time to provide a corporate update and announce results from its 2021 Annual General Meeting of Shareholders.
  • Among the discussion topics will be an update on HIVE's upgrades to its facilities in Iceland and Sweden.
  • Frank Holmes, Interim Executive Chairman; Darcy Daubaras, Chief Financial Officer; Aydin Kilic, President and COO; and Adam Sharp, editor of the HIVE Newsletter, will present.
  • About HIVE Blockchain Technologies Ltd.
    HIVE Blockchain Technologies Ltd. is a growth oriented, TSX.V-listed company building a bridge from the blockchain sector to traditional capital markets.

Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia

Retrieved on: 
Monday, December 20, 2021
Forward-looking statement, HBF, Failure, HPFH, U.S. Securities and Exchange Commission, Food, Fetal hemoglobin, CRISPR, FDA, Survival rate, Death, Beta thalassemia, Company, HBG2, Clinical trial, Life, TDT, Private Securities Litigation Reform Act, Nasdaq, IND, Incidence, Iron overload, Organ dysfunction, Annual report, Sickle cell disease, Anemia, HBG1, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Patient, Disease, DNA, Medicine, Genetic distance, Manifest and latent functions and dysfunctions, GLOBE, Trial of the century, RNP, SCD, CD34, Technology, Phosphorus, Pharmaceutical industry, Vaccine, Editas Medicine, Cpf1

CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND for EDIT-301 for the treatment of transfusion-dependent beta thalassemia (TDT), enabling the Company to initiate a Phase 1/2 clinical study of EDIT-301 in TDT patients.

Key Points: 
  • The FDAs clearance of our IND for EDIT-301 for TDT is an important milestone for Editas and for the patients we hope to serve.
  • With this IND clearance, Editas Medicine is preparing to initiate a Phase 1/2 trial designed to assess the safety, tolerability, and preliminary efficacy of EDIT-301 for the treatment of TDT.
  • Based on clinical severity and transfusion requirements, beta thalassemia can be classified into non-transfusion-dependent (NTDT) and transfusion-dependent beta thalassemia.
  • EDIT-301 is an experimental cell therapy medicine under investigation for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).